{"id":26125,"date":"2024-04-07T23:24:00","date_gmt":"2024-04-07T23:24:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4381461_AE81461_0"},"modified":"2024-04-07T23:24:00","modified_gmt":"2024-04-07T23:24:00","slug":"smart-trial-one-year-data-demonstrates-medtronic-evolut-tavr-platform-as-optimal-treatment-for-severe-aortic-stenosis-in-patients-with-small-annulus-which-is-primarily-women","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=26125","title":{"rendered":"SMART trial one-year data demonstrates Medtronic Evolut\u2122 TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women"},"content":{"rendered":"
\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien\u2122 at one year<\/i><\/p>\n

DUBLIN<\/span> and ATLANTA<\/span>, April 8, 2024<\/span> \/PRNewswire\/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published<\/a> in The New England Journal of Medicine<\/i>. The one-year results of the SM<\/b>all A<\/b>nnuli R<\/b>andomized T<\/b>o Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut\u2122 TAVR platform compared to the SAPIEN\u2122 platform.<\/p>\n

"SMART was launched to better understand how the two most commonly used TAVR systems perform in patients with small aortic annuli, and particularly in women who tend to have smaller heart valves," said Nina Goodheart<\/span>, senior vice president and president, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. "We continue to develop evidence to better understand the benefits of our Evolut TAVR technology in all patients, including patient populations that are underrepresented, under-diagnosed and under-treated. The results from the SMART trial demonstrate these benefits in a large patient population and reinforce our commitment to driving health equity and engineering the best technology to solve unmet patient needs."<\/p>\n

In addition to being the largest comparative trial of TAVR, SMART is also the largest TAVR trial to date to enroll primarily women (87%). Symptomatic severe aortic stenosis can be fatal if left untreated and the average patient survival is two years without treatment.1<\/sup> Despite women’s longer life expectancy, once impacted by severe aortic stenosis they suffer from higher mortality than men, even after matching for age.2<\/sup> Both TAVR and surgical aortic valve replacement (SAVR) are options for women to treat AS. Due to their smaller aortic annuli, women can often receive a valve replacement that does not properly fit their anatomy \u2014 highlighting the need for clinical evidence to inform the best treatment approaches.3<\/sup> Additionally, despite prevalence of chronic conditions associated with AS in women over 65, a new survey of over 1,000 women announced today<\/a> found that the majority have never been referred to a cardiologist. <\/p>\n

"As clinicians, we know that tailored approaches are needed to address the unique presentation of AS in the small annulus patient population, which is primarily women. Little comparative data exists to help us with valve selection," said Howard C. Herrmann<\/span>, M.D., Perelman School of Medicine at the University of Pennsylvania<\/span>, Philadelphia, Penn.<\/span>, and lead investigator of the SMART Trial. "While we know women have a greater benefit than men when treated with TAVR vs SAVR, now for the first time there is definitive data demonstrating that women have the best valve performance when treated with the Evolut TAVR system."<\/p>\n

The SMART Trial is an international, prospective, multi-center, randomized (1:1) post-market trial comparing the safety and performance of self-expanding versus balloon-expandable TAVR in patients with symptomatic severe AS and SAA. The trial randomized and treated 716 patients, 87% of which were women, across more than 80 sites worldwide. Eligible patients had a computed tomography aortic valve annulus area of \u2264430 mm2<\/sup> and suitable anatomy for transfemoral TAVR with both an Evolut PRO\/PRO+\/FX or a SAPIEN 3\u2122\/3 Ultra\u2122 valve.<\/p>\n

"For patients with heart valve replacements, early bioprosthetic valve dysfunction can lead to increased risk of serious long term outcomes including mortality and rehospitalization," added Dr. Herrmann. "As clinicians, these data further reinforces that not all valves are the same, and we strongly need to consider valve performance when determining device selection."<\/p>\n

Results demonstrated that the Evolut TAVR platform met both co-primary endpoints of clinical non-inferiority and hemodynamic superiority at one year.<\/p>\n